Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting New Standard in CNS Infection Diagnostics

Reuters

2025/09/11

Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting <a href="https://laohu8.com/S/NSE.AU">New Standard</a> in CNS Infection Diagnostics

Qiagen NV has secured the European CE-IVDR certification for its entire portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel. This certification underscores Qiagen's commitment to providing high-quality diagnostics and aligns with the new European Union regulations for in vitro diagnostics. The QIAstat-Dx panels offer quick and comprehensive results, facilitating early and accurate treatment decisions. The newly certified ME Panel, which provides broad coverage for CNS infections with 16 targets, is set to launch in September 2025. This regulatory approval highlights Qiagen's dedication to advancing diagnostics for life-threatening central nervous system infections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250910286236) on September 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566258984"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566258984\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566258984?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566258984","market":"fut","top_or_hot":-1,"title":"Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting New Standard in CNS Infection Diagnostics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting <a href=\"https://laohu8.com/S/NSE.AU\">New Standard</a> in CNS Infection Diagnostics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qiagen NV has secured the European CE-IVDR certification for its entire portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel. This certification underscores Qiagen's commitment to providing high-quality diagnostics and aligns with the new European Union regulations for in vitro diagnostics. The QIAstat-Dx panels offer quick and comprehensive results, facilitating early and accurate treatment decisions. The newly certified ME Panel, which provides broad coverage for CNS infections with 16 targets, is set to launch in September 2025. This regulatory approval highlights Qiagen's dedication to advancing diagnostics for life-threatening central nervous system infections.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250910286236) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting New Standard in CNS Infection Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting New Standard in CNS Infection Diagnostics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-11 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting <a href=\"https://laohu8.com/S/NSE.AU\">New Standard</a> in CNS Infection Diagnostics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qiagen NV has secured the European CE-IVDR certification for its entire portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel. This certification underscores Qiagen's commitment to providing high-quality diagnostics and aligns with the new European Union regulations for in vitro diagnostics. The QIAstat-Dx panels offer quick and comprehensive results, facilitating early and accurate treatment decisions. The newly certified ME Panel, which provides broad coverage for CNS infections with 16 targets, is set to launch in September 2025. This regulatory approval highlights Qiagen's dedication to advancing diagnostics for life-threatening central nervous system infections.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250910286236) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QGEN","symbol_name":"快而精醫藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDLblsZ70:1","article_id":"2566258984","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566258984","pubTimestamp":1757534727,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire  on September 10, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QGEN":"快而精医药","LU1923622614.USD":"Natixis Thematics Meta R/A USD","BK4121":"生命科学工具和服务","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC"},"translate_title":"Qiagen NV全QIAstat-Dx产品组合获得CE-IVDR认证，树立中枢神经系统感染诊断新标准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting New Standard in CNS Infection Diagnostics\n    \n\n        Qiagen NV has secured the European CE-IVDR certification for its entire portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel. This certification underscores Qiagen's commitment to providing high-quality diagnostics and aligns with the new European Union regulations for in vitro diagnostics. The QIAstat-Dx panels offer quick and comprehensive results, facilitating early and accurate treatment decisions. The newly certified ME Panel, which provides broad coverage for CNS infections with 16 targets, is set to launch in September 2025. This regulatory approval highlights Qiagen's dedication to advancing diagnostics for life-threatening central nervous system infections.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250910286236) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}